A
ADCendo
A Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers
About ADCendo
Adcendo is a biotechnology startup that specializes in the development of antibody-drug conjugates (ADCs), a type of cancer treatment that targets specific cancer cells. The company was founded in 2017 as a spin-off from the University of Copenhagen and Rigshospitalet. Its founders, Niels Behrendt, Lars Engelholm, and Christoffer Nielsen, have over 20 years of experience in cancer research and drug development.
Read full description
Adcendo's primary focus is on the uPARAP receptor, a molecule involved in cancer development and metastasis. The founders have demonstrated that ADCs targeting this receptor can effectively treat cancer in preclinical models. This discovery led to the creation of Adcendo, which aims to further investigate and develop these findings into viable cancer treatments.
The company operates in the biotechnology and pharmaceutical market, serving clients such as hospitals, healthcare providers, and potentially, cancer patients. Its business model revolves around the research, development, and commercialization of its ADCs. Revenue is generated through the successful development and sale of these cancer treatments, as well as through partnerships with other biotech and pharmaceutical companies.
In 2021, Adcendo secured 51 million EUR in a series A investment round, which was extended by an additional 31 million EUR in 2023. This funding, provided by an international syndicate of life science and biotech investors, will support the company's ongoing research and development efforts.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Copenhagen, Denmark
- Employees
- 63
- Open positions
- None listed
- Dealroom signal
- 67.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, Nordic Rising Star 2022, Top 50 Nordic Rising Star 2022 Denmark, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2026 | $70M | $712M | TPG · Bpifrance · Ysios Capital · Venrock | ↗ |
| SERIES BOther financing | Nov 2024 | $142M | $570M | Ysios Capital · HealthCap · Gilde Healthcare · OrbiMed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for ADCendo is 3.6K monthly website visits, up 89.5% over the last three months. ADCendo's team declined 4.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Novo Nordisk Foundation
Series A14 investors entered at this stage
Ysios Capital
HealthCap
Novo Seeds
Gilde Healthcare
RA Capital Management
Pontifax Funds
Novo Holdings
Dawn Biopharma
TCGX
OrbiMed
Logos Capital
Surveyor Capital
TPG
Venrock
Series B and later4 investors entered at this stage
Jeito Capital
Bpifrance
Vida Ventures
Export and Investment Fund of Denmark
Other known investors2 additional known investors
Rigshospitalet
University of Copenhagen
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ADCendo on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ADCendo’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.